Cyrille Leperlier
Fortuna: - $ al 31/03/2024
Fortuna: - $ al 31/03/2024
Cyrille Raymond George Leperlier is currently an Independent Non-Executive Director at NuCana Plc since 2018.
Formerly, the role of Chief Executive Officer was held at Divlal SAS from 2020 to 2022.
The position of Medical Director was held at Rhone-Poulenc Rorer, Inc. Medical Director at Sanofi-Aventis Japan was held from 2014 to 2019.
Education includes graduate and doctorate degrees from the University of Paris Jussieu.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NUCANA PLC -.--% | 18/03/2026 | 0 ( -.--% ) | - $ | 31/03/2024 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NUCANA PLC | Director/Miembro de la Junta | 01/05/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
Divlal SAS | Director Ejecutivo | 01/11/2022 |
Sanofi-Aventis Japan | Director Técnico/Científico/I+D | 01/12/2019 |
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and markets human pharmaceuticals | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and markets human pharmaceuticals | Health Technology |
University of Paris Jussieu
University of Paris Jussieu Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis Japan | |
NuCana Plc
NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Divlal SAS |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.